← Back to all trials
Enrolling By Invitation
NCT06926621
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
Conditions: Myotonic Dystrophy Type 1 (DM1)
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 44
Sponsor: Vertex Pharmaceuticals Incorporated
Location: St. Louis Children's Hospital - Neurology St Louis Missouri
Summary
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Eligibility Criteria
Key Inclusion Criteria:
• Completed study drug treatment in parent study VX23-670-001 (NCT06185764)
Key Exclusion Criteria:
• History of any illness or any clinical condition as pre-specified in the protocol
Other protocol defined Inclusion/Exclusion criteria may apply.
Source: ClinicalTrials.gov (NCT06926621). StuddyBuddy aggregates publicly available trial information.
